# A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

> **NCT06055374** · PHASE1 · WITHDRAWN · sponsor: **Brexogen Inc.**

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** BxC-I17e
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06055374
- **Lead sponsor:** Brexogen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-01
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was integrated into BRE-AD01-001 study
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06055374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06055374, "A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06055374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*